Subgroup analysis based on IDH1/2 mutation status showed higher OS in the combination therapy group [36] Acquired biallelic silencing of TP53 correlated with initial responsiveness followed by refractoriness in older patients with AML [87]. Here, IDH1 is linked to acute myeloid leukemia.